Abstract
High-dose chemotherapy with autologous bone-marrow transplantation is active in non-Hodgkin lymphoma patients. The results of randomized trials in the setting of consolidation of first complete remission are not in favor of use of high-dose chemotherapy. However preliminary results of pilot studies are in favor of this treatment in reponder patients. The results of the PARMA protocol will help to answer the question.
Publication types
-
Comparative Study
-
English Abstract
-
Meta-Analysis
MeSH terms
-
Adolescent
-
Adult
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bone Marrow Transplantation
-
Child
-
Child, Preschool
-
Combined Modality Therapy
-
Dose-Response Relationship, Drug
-
Female
-
Follow-Up Studies
-
Humans
-
Lymphoma, Non-Hodgkin / drug therapy
-
Lymphoma, Non-Hodgkin / therapy*
-
Male
-
Registries
-
Salvage Therapy
-
Survival Rate